ERK2 (MAPK1) (C-term) (incl. pos. control) Mouse Monoclonal Antibody [Clone ID: 6G11]

CAT#: AM00085BT-N

ERK2 (MAPK1) (C-term) (incl. pos. control) mouse monoclonal antibody, clone 6G11, Biotin

Specifications

Product Data

• Clone Name: 6G11
• Applications: ELISA, IP, WB
• Recommended Dilution: ELISA: Use at 0.05 µg/ml.
  Immunoblotting: 0.5 µg/ml for HRPO/ECL detection.
  Recommended blocking buffer: Casein/Tween 20 based blocking and blot incubation buffer AS00002BU-N or AS00002BU-L.
  Immunoprecipitation: 1-10 µg/ml per 10e6 pervanadate-treated A431 cells.
  Included Positive Control: Cell lysate from untreated HepG2 cells (See Protocols for more details).
• Reactivities: Canine, Human, Mouse, Rat
• Host: Mouse
• Isotype: IgG1
• Clonality: Monoclonal
• Immunogen: Peptide conjugated to KLH
  Epitope: C-terminus
• Specificity: This antibody specifically recognizes the C-terminus of MAP kinase 2 (ERK2). It does not crossreact with MAP kinase 1 (ERK1).
• Formulation: PBS with 0.09% Sodium Azide/PEG and Sucrose.
  Label: Biotin
  State: Liquid purified IgG fraction.
• Concentration: lot specific
• Purification: Subsequent Thiophilic Adsorption and Size Exclusion Chromatography.
• Conjugation: Biotin
• Storage: Aliquote and freeze in liquid nitrogen
  Antibody can be stored frozen at -80°C up to 1 year.
  Thaw aliquots at 37°C. Thawed
  aliquots may be stored at 4°C up to 3 months.
• Gene Name: mitogen-activated protein kinase 1
• Database Link:
  Entrez Gene 26413 MouseEntrez Gene 116590 RatEntrez Gene 5594 Human
  UniProt ID P28482
• Background: Extracellular signal/mitogen activated protein kinases (erk/MAPK) are a group of proline-directed serine/threonine kinases that are activated by dual phosphorylation of conserved threonine and tyrosine residues within a characteristic T X Y peptide motif. The mitogen-activated kinases erk1 (MAPK1) and erk2 (MAPK2) acquire full enzymatic activity upon phosphorylation of both threonine and tyrosine residues within the sequence motif T E Y.
• Synonyms: Mitogen-activated protein kinase 1, p42-MAPK, ERT1, PRKM1, PRKM2, MAP kinase 2, MAPK2, MAPK1
• Note: Mol. weight: 42 kDa
  
  Protocol: Positive Control Provided.
  Cell lysate from untreated HepG2
  
  Description: Cell lysate from untreated HepG2 cells, hepatocellular carcinoma (human)
  
  Format: Lyophilized cell lysate from serum starved HepG2 cells.
  
  Reconstitution:Restore by addition of 200 µl H20. After complete solubilization add 200 µl 2x SDS-PAGE sample buffer, mix and incubate at 90°C for 5 min.
  
  Storage: Aliquote and store frozen.
  Avoid repeated freeze/thaw cycles.
  
  Application: The positive control cell lysate is recommended for immunoblot applications. 20 µl of positive control cell lysate correspond to ca. 80.000 cells. Use 20 µl / lane (mini gel) for HRPO/ECL detection of the target proteins.
  Please note: The lyophilized cell lysates contain SDS and are not recommended for applications with native proteins such as immunoprecipitation.

Reference Data

• Protein Families: Druggable Genome, Protein Kinase
• Protein Pathways: Acute myeloid leukemia, Adherens junction, Alzheimer's disease, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Chemokine signaling pathway, Chronic myeloid leukemia, Colorectal cancer, Dorso-ventral axis formation, Endometrial cancer, ErbB signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, Gap junction, Glioma, GnRH signaling pathway, Insulin signaling pathway, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, mTOR signaling pathway, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, NOD-like receptor signaling pathway, Non-small cell lung cancer, Oocyte meiosis, Pancreatic cancer, Pathways in cancer, Prion diseases, Progesterone-mediated oocyte maturation, Prostate cancer, Regulation of actin cytoskeleton, Renal cell carcinoma, T cell receptor signaling pathway, TGF-beta signaling pathway, Thyroid cancer, Toll-like receptor signaling pathway, Type II diabetes mellitus, Vascular smooth muscle contraction, VEGF signaling pathway